Kidney Disease Complexity Manifested: One Biomarker Size Does Not Fit All.
作者信息
Shankar Mythri, Goldstein Stuart L
机构信息
Department of Internal Medicine, Institute of Nephro-Urology, Bengaluru, India.
Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
出版信息
Kidney Int Rep. 2022 Jun 3;7(7):1458-1460. doi: 10.1016/j.ekir.2022.05.037. eCollection 2022 Jul.
Abstract
摘要
相似文献
1
Kidney Disease Complexity Manifested: One Biomarker Size Does Not Fit All.肾脏疾病复杂性显现：一种生物标志物并不适用于所有情况。
Kidney Int Rep. 2022 Jun 3;7(7):1458-1460. doi: 10.1016/j.ekir.2022.05.037. eCollection 2022 Jul.
2
Biomarkers for Diagnosis and Prognosis of AKI in Children: One Size Does Not Fit All.儿童急性肾损伤的诊断和预后标志物：一种方法并不适合所有情况。
Clin J Am Soc Nephrol. 2017 Sep 7;12(9):1551-1557. doi: 10.2215/CJN.12851216. Epub 2017 Jun 30.
3
Partial Versus Radical Nephrectomy: Complexity of Decision-Making and Utility of AUA Guidelines.部分肾切除术与根治性肾切除术：决策的复杂性和 AUA 指南的实用性。
Clin Genitourin Cancer. 2022 Dec;20(6):501-509. doi: 10.1016/j.clgc.2022.06.003. Epub 2022 Jun 9.
4
Effect of ulcerative colitis duration on the usefulness of immunochemical fecal occult blood test result as a disease activity biomarker.溃疡性结肠炎病程对免疫化学粪便隐血试验结果作为疾病活动生物标志物的有用性的影响。
Int J Colorectal Dis. 2020 Sep;35(9):1729-1739. doi: 10.1007/s00384-020-03636-5. Epub 2020 May 29.
5
Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening.高性能生物标志物检测与粪便免疫化学检测用于非侵入性结直肠癌筛查的成本效益比较。
Clin Gastroenterol Hepatol. 2018 Apr;16(4):504-512.e11. doi: 10.1016/j.cgh.2017.07.011. Epub 2017 Jul 18.
6
Preoperative masked renal damage in Japanese patients with primary aldosteronism: identification of predictors for chronic kidney disease manifested after adrenalectomy.日本原发性醛固酮增多症患者术前隐匿性肾损害：肾上腺切除术后慢性肾脏病表现的预测因子。
Int J Urol. 2013 Jul;20(7):685-91. doi: 10.1111/iju.12029. Epub 2012 Nov 27.
7
Assessment of disease activity by fecal immunochemical test in ulcerative colitis.通过粪便免疫化学检测评估溃疡性结肠炎的疾病活动度。
World J Gastroenterol. 2016 Dec 28;22(48):10617-10624. doi: 10.3748/wjg.v22.i48.10617.
8
Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease: A Biomarker of Disease Progression and Therapeutic Efficacy.常染色体显性多囊肾病的总肾体积：疾病进展和治疗效果的生物标志物。
Am J Kidney Dis. 2015 Oct;66(4):564-76. doi: 10.1053/j.ajkd.2015.01.030. Epub 2015 May 7.
9
New-onset Chronic Kidney Disease After Surgery for Localised Renal Masses in Patients with Two Kidneys and Preserved Renal Function: A Contemporary Multicentre Study.双侧肾脏且肾功能正常的患者行局限性肾肿块手术后新发慢性肾脏病：一项当代多中心研究
Eur Urol Open Sci. 2023 May 5;52:100-108. doi: 10.1016/j.euros.2023.04.011. eCollection 2023 Jun.
10
Functional immunoassay technology (FIT), a new approach for measuring physiological functions: application of FIT to measure glomerular filtration rate (GFR).功能性免疫测定技术（FIT），一种测量生理功能的新方法：FIT在测量肾小球滤过率（GFR）中的应用。
Am J Physiol Renal Physiol. 2008 Nov;295(5):F1583-8. doi: 10.1152/ajprenal.90354.2008. Epub 2008 Sep 3.
引用本文的文献
1
Clinical courses of acute kidney injury in hospitalized patients: a multistate analysis.住院患者急性肾损伤的临床病程：一项多州分析。
Sci Rep. 2023 Oct 18;13(1):17781. doi: 10.1038/s41598-023-45006-5.
本文引用的文献
1
Biomarkers of Kidney Tubule Disease and Risk of End-Stage Kidney Disease in Persons With Diabetes and CKD.糖尿病和慢性肾脏病患者肾小管疾病的生物标志物与终末期肾病风险
Kidney Int Rep. 2022 Apr 5;7(7):1514-1523. doi: 10.1016/j.ekir.2022.03.033. eCollection 2022 Jul.
2
Considerations in Controlling for Urine Concentration for Biomarkers of Kidney Disease Progression After Acute Kidney Injury.急性肾损伤后控制尿浓度以评估肾病进展生物标志物的相关考量
Kidney Int Rep. 2022 Apr 6;7(7):1502-1513. doi: 10.1016/j.ekir.2022.03.026. eCollection 2022 Jul.
3
Recommendations on Acute Kidney Injury Biomarkers From the Acute Disease Quality Initiative Consensus Conference: A Consensus Statement.急性疾病质量倡议共识会议关于急性肾损伤生物标志物的建议：共识声明。
JAMA Netw Open. 2020 Oct 1;3(10):e2019209. doi: 10.1001/jamanetworkopen.2020.19209.
4
Differential diagnosis of AKI in clinical practice by functional and damage biomarkers: workgroup statements from the tenth Acute Dialysis Quality Initiative Consensus Conference.通过功能和损伤生物标志物对临床实践中急性肾损伤进行鉴别诊断：第十届急性透析质量倡议共识会议工作组声明
Contrib Nephrol. 2013;182:30-44. doi: 10.1159/000349964. Epub 2013 May 13.
5
Combining creatinine and volume kinetics identifies missed cases of acute kidney injury following cardiac arrest.结合肌酐和容量动力学可识别心脏骤停后急性肾损伤的漏诊病例。
Crit Care. 2013 Jan 17;17(1):R7. doi: 10.1186/cc11931.
6
Acute kidney injury in patients with acute lung injury: impact of fluid accumulation on classification of acute kidney injury and associated outcomes.急性肺损伤患者的急性肾损伤：液体蓄积对急性肾损伤分类及相关结局的影响。
Crit Care Med. 2011 Dec;39(12):2665-71. doi: 10.1097/CCM.0b013e318228234b.
7
Diagnosis of acute kidney injury: from classic parameters to new biomarkers.急性肾损伤的诊断：从经典指标到新型生物标志物
Contrib Nephrol. 2007;156:213-9. doi: 10.1159/000102086.
8
Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.生物标志物与替代终点：首选定义及概念框架
Clin Pharmacol Ther. 2001 Mar;69(3):89-95. doi: 10.1067/mcp.2001.113989.
Zotero 插件